<DOC>
	<DOC>NCT00802087</DOC>
	<brief_summary>The purpose of the study is to evaluate the pharmacokinetic profile of different Egalet® hydrocodone formulations and compare to a marketed hydrocodone drug.</brief_summary>
	<brief_title>Single Dose Pharmacokinetics of Egalet® Hydrocodone</brief_title>
	<detailed_description>Outcomes: Pharmacokinetic parameters and bioequivalence testing.</detailed_description>
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Nonsmokers ≥18 and ≤55 years of age BMI ≥19 and ≤30.0 Clinically significant abnormalities, physical or psychological illnesses or conditions contraindicating hydrocodone treatment History of significant abuse, dependance or addiction of alcohol, drugs or hard drugs within one year prior to screening Allergic to hydrocodone, hydromorphone, other opioids, or related drugs Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to study drug administration Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hydrocodone</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety &amp; Tolerability</keyword>
</DOC>